- Home
- PPSI vs KYNB Comparison
PPSI vs KYNB Comparison
Compare PPSI & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PPSI | KYNB |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 31.9M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | PPSI | KYNB |
|---|---|---|
| Price | $3.25 | $6.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 70.6K | 28.6K |
| Earning Date | 05-14-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1626.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,879,000.00 | N/A |
| Revenue This Year | $26.84 | N/A |
| Revenue Next Year | $10.26 | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.26 | $6.38 |
| 52 Week High | $5.70 | $9.58 |
Technical Indicators
Market Signals| Indicator | PPSI | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 35.48 |
| Support Level | $2.96 | N/A |
| Resistance Level | $4.05 | $7.58 |
| Average True Range (ATR) | 0.24 | 0.36 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 12.26 | 2.19 |
Price Performance
Historical ComparisonAbout PPSI Pioneer Power Solutions Inc.
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions.. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.